VRTX Earnings
Upcoming earnings date and last 8 quarters of EPS surprise.
Next Earnings
EPS Surprise — Last 8 Quarters
Quarterly Detail
| Quarter | Report Date | Est EPS | Actual EPS | Surprise % | Result |
|---|---|---|---|---|---|
| Q1 2026 | May 4, 2026 | 4.31 | 4.47 | +3.81% | Beat |
| Q4 2025 | Feb 12, 2026 | 5.15 | 5.03 | -2.30% | Miss |
| Q3 2025 | Nov 3, 2025 | 4.58 | 4.80 | +4.87% | Beat |
| Q2 2025 | Aug 4, 2025 | 4.25 | 4.52 | +6.33% | Beat |
| Q1 2025 | May 5, 2025 | 4.29 | 4.06 | -5.44% | Miss |
| Q4 2024 | Feb 10, 2025 | 4.02 | 3.98 | -1.00% | Inline |
| Q3 2024 | Nov 4, 2024 | 4.13 | 4.38 | +5.96% | Beat |
| Q2 2024 | Aug 1, 2024 | -11.75 | -12.83 | -9.17% | Miss |
Recent Guidance Mentions (8-K)
- May 4, 2026 · 8-K
harmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the first quarter ended March 31, 2026, and reiterated its full year 2026 financial guidance. “Vertex is off to a strong start in 2026, driven by leadership in cystic fibrosis; growth in sickle cell disease, beta thalassemia, and acute pain; as well as rapid pipeline p
View 8-K filing → - May 4, 2026 · 8-K
R&D and SG&A expenses guidance relates primarily to $650 million to $700 million of stock-based compensation expense. **Combined GAAP and non-GAAP R&D, AIPR&D and SG&A expenses guidance includes approximately $100 million of AIPR&D expenses. Key Business Highlights Marketed Products Cystic Fibrosis (CF) Portfolio Vertex has worked for more than 20 years to dis
View 8-K filing → - May 4, 2026 · 8-K
ccordance with accounting principles generally accepted in the United States (GAAP) and using certain non-GAAP financial measures. In particular, non-GAAP financial results and guidance exclude from Vertex's pre-tax income (i) stock-based compensation expense, (ii) intangible asset amortization expense, (iii) gains or losses related to the fair value of the co
View 8-K filing →
Data updated May 25, 2026 · source: Yahoo Finance via yfinance